| |
|
Number 03 - MARCH 2006 COLORECTAL CANCER - MOLECULAR BIOLOGY Deschoolmeester V, Baay M, Wuyts W, Marck EV, Pelckmans P, Lardon F, Vermorken JB. Comparison of three commonly used PCR-based techniques to analyze MSI status in sporadic colorectal cancer. J Clin Lab Anal. 2006;20(2):52-61.
Sebzda T, Saleh Y, Gburek
J, Warwas M, Andrzejak R, Siewinski M, Rudnicki J.
Total and lipid-bound plasma sialic acid as diagnostic markers in
colorectal cancer patients: correlation with cathepsin B expression
in progression to Dukes stage. Berger BM, Schroy PC 3rd, Rosenberg JL, Lai-Goldman M, Eisenberg M, Brown T, Rochelle RB, Billings PR. Colorectal cancer screening using stool DNA analysis in clinical practice: early clinical experience with respect to patient acceptance and colonoscopic follow-up of abnormal tests. Clin Colorectal Cancer. 2006 Jan;5(5):338-43.
Vincenzi B, Santini D,
Russo A, Silletta M, Gavasci M, Battistoni F, Di Cuonzo G, Rocci L,
Gebbia N, Tonini G.
Angiogenesis modifications related with cetuximab plus irinotecan as
anticancer treatment in advanced colorectal cancer patients. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T, Barad O, Bentwich Z, Szafranska AE, Labourier E, Raymond CK, Roberts BS, Juhl H, Kinzler KW, Vogelstein B, Velculescu VE. The colorectal microRNAome. Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3687-92. Hibi K, Nakao A. Lymph node metastasis is infrequent in patients with highly-methylated colorectal cancer. Anticancer Res. 2006 Jan-Feb;26(1A):55-8. Yoon SS, Kim SH, Gonen M, Heffernan NM, Detwiller KY, Jarnagin WR, D'Angelica M, Blumgart LH, Tanabe KK, Dematteo RP. Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol. 2006 Mar;13(3):353-62.
Shiono S, Ishii G, Nagai
K, Murata Y, Tsuta K, Nitadori J, Kodama T, Ochiai A.
Immunohistochemical prognostic factors in resected colorectal lung
metastases using tissue microarray analysis. Fraser CG, Matthew CM, Mowat NA, Wilson JA, Carey FA, Steele RJ. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study. Lancet Oncol. 2006 Feb;7(2):127-31. Giribaldi G, Procida S, Ulliers D, Mannu F, Volpatto R, Mandili G, Fanchini L, Bertetto O, Fronda G, Simula L, Rimini E, Cherchi G, Bonello L, Maule MM, Turrini F. Specific detection of cytokeratin 20-positive cells in blood of colorectal and breast cancer patients by a high sensitivity real-time reverse transcriptase-polymerase chain reaction method. J Mol Diagn. 2006 Feb;8(1):105-12. Chialina SG, Fornes C, Landi C, de la Vega Elena CD, Nicolorich MV, Dourisboure RJ, Solano A, Solis EA. Microsatellite instability analysis in hereditary non-polyposis colon cancer using the Bethesda consensus panel of microsatellite markers in the absence of proband normal tissue. BMC Med Genet. 2006 Jan 20;7:5. Famulski W, Sulkowska M, Wincewicz A, Kedra B, Pawlak K, Zalewski B, Sulkowski S, Koda M, Baltaziak M. P53 correlates positively with VEGF in preoperative sera of colorectal cancer patients. Neoplasma. 2006;53(1):43-8. Iinuma H, Okinaga K, Egami H, Mimori K, Hayashi N, Nishida K, Adachi M, Mori M, Sasako M. Usefulness and clinical significance of quantitative real-time RT-PCR to detect isolated tumor cells in the peripheral blood and tumor drainage blood of patients with colorectal cancer. Int J Oncol. 2006 Feb;28(2):297-306. Matsuzaki K, Deng G, Tanaka H, Kakar S, Miura S, Kim YS. The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8564-9. Gordon MA, Gil J, Lu B, Zhang W, Yang D, Yun J, Schneider S, Groshen S, Iqbal S, Press OA, Rhodes K, Lenz HJ. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics. 2006 Jan;7(1):67-88. Syngal S, Stoffel E, Chung D, Willett C, Schoetz D, Schroy P, Jagadeesh D, Morel K, Ross M. Detection of stool DNA mutations before and after treatment of colorectal neoplasia. Cancer. 2006 Jan 15;106(2):277-83. Benatti P, Gafa R, Barana D, Marino M, Scarselli A, Pedroni M, Maestri I, Guerzoni L, Roncucci L, Menigatti M, Roncari B, Maffei S, Rossi G, Ponti G, Santini A, Losi L, Di Gregorio C, Oliani C, Ponz de Leon M, Lanza G. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res. 2005 Dec 1;11(23):8332-40. Duff SE, Jeziorska M, Rosa DD, Kumar S, Haboubi N, Sherlock D, O'Dwyer ST, Jayson GC. Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur J Cancer. 2006 Jan;42(1):112-7. Sadahiro S, Suzuki T, Ishikawa K, Saguchi T, Maeda Y, Yasuda S, Makuuchi H, Yurimoto S, Murayama C. Detection of carcinoembryonic antigen messenger RNA-expressing cells in portal and peripheral blood during surgery does not influence relapse in colorectal cancer. Ann Surg Oncol. 2005 Dec;12(12):988-94. Barrier A, Boelle PY, Lemoine A, Tse C, Brault D, Chiappini F, Lacaine F, Houry S, Huguier M, Flahault A, Dudoit S. Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients. Dis Colon Rectum. 2005 Dec;48(12):2238-48. Zlobec I, Steele R, Compton CC. VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. Cancer. 2005 Dec 1;104(11):2517-21. Ward RL, Turner J, Williams R, Pekarsky B, Packham D, Velickovic M, Meagher A, O'Connor T, Hawkins NJ. Routine testing for mismatch repair deficiency in sporadic colorecl cancer is justified. J Pathol. 2005 Dec;207(4):377-84.
Engel C, Forberg J, Holinski-Feder E,
Pagenstecher C, Plaschke J, Kloor M, Poremba C, Pox CP, Ruschoff J,
Keller G, Dietmaier W, Rummele P, Friedrichs N, Mangold E, Buettner
R, Schackert HK, Kienle P, Stemmler S, Moeslein G, Loeffler M;
German HNPCC Consortium.
Novel strategy for optimal sequential application of clinical
criteria, immunohistochemistry and microsatellite analysis in the
diagnosis of hereditary nonpolyposis colorectal cancer. |
